key: cord-0786791-ae865hl4 authors: Woodfield, Maresa C.; Pergam, Steven A.; Shah, Parth D. title: Cocooning against COVID‐19: The argument for vaccinating caregivers of patients with cancer date: 2021-04-23 journal: Cancer DOI: 10.1002/cncr.33598 sha: be59b3ea66b2d09460e62952c22dae00cc310341 doc_id: 786791 cord_uid: ae865hl4 Current national COVID‐19 vaccination guidelines and recommendations focus vaccine guidance on patients with cancer. In this COVID‐19 vaccination race, “cocoon vaccination” strategies which include informal caregivers and household contacts as priority groups for SARS‐CoV‐2 vaccination could be an additional strategy used to protect patients with cancer who may have limited immune responses to current vaccinations. Medical systems specializing in cancer care should support education and vaccination campaigns which target informal caregivers and household contacts in addition to cancer patients. populations are crucial, but results will not be available before we must make decisions. We believe additional creative strategies to prevent COVID-19 must complement vaccination of patients with cancer, particularly as we wait for vaccines to become more readily available and as new SARS-CoV-2 variants threaten to undermine the realized effectiveness of our current first-generation vaccines. Addressing the theoretical risk that patients with cancer could play in the development of these viral variants is even more important. 13 Herd immunity, sometimes called community or population immunity, prevents transmission of communicable diseases by limiting an infected person's susceptible contacts. Reaching thresholds high enough to achieve herd immunity stops spread within larger populations; immune or even partially immune community members protect the nonimmune. Measles, a disease that is more infectious than SARS-CoV-2, was eliminated from the United States as high community seroprevalence demonstrated this effect by eliminating local transmission. 14 Unfortunately, as measles, mumps, and rubella vaccination rates have waned, measles outbreaks have become more frequent. 15 In the midst of our current COVID-19 pandemic, our limited vaccine supply means that reaching herd immunity by vaccinating a significant proportion of the population remains a distant goal; worryingly, this herd immunity "finish line" is moving further away in our vaccination race, as more contagious SARS-CoV-2 variants emerge in our communities. However, deliberate use of our current vaccine supply could leverage herd immunity concepts to protect our most vulnerable community members. Moving the caregivers and household contacts of patients with cancer higher in vaccine prioritization would create a protective layer of vaccinated family and household contacts buffering patients with cancer from exposure. This approach, so-called "cocooning," has been used to protect newborns 16 and other immunosuppressed populations 17,18 who either cannot receive live-virus vaccines or are known to have poor immunologic responses to other recommended vaccines. A classic example of this strategy has been to revaccinate adults to prevent late acquisition and transmission of the bacterial pathogen that leads to life-threatening pertussis (whooping cough) in newborns. 16 A cocooning vaccination strategy seems particularly appropriate for COVID-19 because households remain one of the most common sources of transmission. A recent meta-analysis showed secondary attack rates to be 17% in households. 19 Patients with cancer require significant support from caregivers, relying on them to go out in the community for medications, food, and other necessities. A patient with cancer who follows protective behavioral measures such as social distancing and masking may be put at undue risk to SARS-CoV-2 exposure because their critical support members and close contacts must enter the community. The Advisory Committee on Immunization Practices and other guidelines recommend close contacts of immunosuppressed patients receive all routine vaccines for other communicable diseases, 20,21 but their current COVID-19 vaccination recommendations do not call-out informal caregivers or household contacts of high-risk individuals in their prioritization schema. 22 The potential benefits of this strategy warrants strong consideration, but cocooning is not without its own weaknesses. This approach, in part, assumes that COVID-19 vaccines reduce viral transmission. Although this is highly possible, clinical trial data have not currently provided conclusive evidence whether vaccinated individuals are less likely to acquire and transmit SARS-CoV-2. However, studies have shown that symptomatic household members are more likely to transmit infection, 19 and available vaccines have been shown to be exceptionally efficacious at limiting moderate to severe COVID-19. Furthermore, if ongoing limits to the vaccine supply prevent all caregivers and household contacts from receiving vaccines, we may need to prioritize those caring for the highest risk patients with cancer such as those undergoing active chemotherapy, hematopoietic cell transplantation, or cellular therapy. Beyond changing prioritization schema, mobilizing a cocooning approach for caregivers and household contacts of cancer and other immunosuppressed patients will require investment in vaccine education and targeted messaging to these groups to assure high-level vaccine uptake. Previous surveys have shown patients with cancer strongly believe it is important for their caregivers to receive seasonal flu vaccines, 23 yet 32% of US residents polled in a recent Centers for Disease Control and Prevention study reported they were not likely to get a COVID-19 vaccine. 24 Vaccine acceptance drops even more among Blacks and African Americans, one of the populations hardest hit by the pandemic. 24 Yet, despite the importance of vaccines in preventing infectious complications in patients with cancer, a recent study of National Cancer Institute-designated cancer centers showed only 11% of vaccine education on their websites specifically targeting caregivers. 25 Medical systems who care for high-risk patients-namely cancer and transplant centers-are ideally suited to identify these close contacts and to ensure vaccine education and appropriate distribution reaches them in a timely manner. By allowing cancer centers to Cancer Month 0, 2021 provide vaccines, clinic visits could easily double as vaccine appointments for both the patient and their eligible caregiver. The oncology community has a responsibility to both advocate for patient and caregiver vaccinations and support efforts to assure equitable vaccine distribution among their patient populations. Over the last year, the power of creative scientific thinking has generated many innovative and effective pandemic mitigation strategies. We should be similarly as open-minded when developing our vaccine allocation strategies. The approach of vaccinating only high-risk patients cannot be the lone solution we rely on to protect our country's most vulnerable. Instead, the cancer community should target vaccines and vaccine education to caregivers and household contacts as one of our major pillars of COVID-19 prevention. We recognize that our proposal is not without its implementation challenges, however, it does offer opportunities for multidisciplinary collaboration and problem solving that could lead to sustainable vaccination models for major communicable pathogens, especially if COVID-19 becomes another endemic disease in our society. 26 It is time we ensure that the home of a patient with cancer remains a refuge for their therapy and not an epicenter of transmission. Steven A. Pergam receives research support from Global Life Technologies, Inc; participates in research trials with Chimerix, Inc, and Merck & Co; and has participated in a clinical trial sponsored by the National Institute of Allergy and Infectious Diseases (U01-AI132004) for which vaccines were provided by Sanofi Aventis. None of these companies or agencies were involved in this study. The other authors made no disclosures. Priority COVID-19 vaccination for patients with cancer while vaccine supply is limited National Comprehensive Care Network. Preliminary recommendations of the NCCN COVID-19 Vaccination Advisory Committee ASH-ASTCT COVID-19 vaccination for HCT and CAR T cell recipients: frequently asked questions Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): a systemic infection Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study Clinical characteristics and outcomes of COVID-19 in haematopoietic stem-cell transplantation recipients: an observational cohort study Letter to President Biden and leaders of state public health departments: prioritizing COVID-19 vaccines for patients with cancer and survivors of cancer Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine Vaccination of the stem cell transplant recipient and the hematologic malignancy patient Randomized double-blind study of the safety and immunogenicity of standard-dose trivalent inactivated influenza vaccine versus high-dose trivalent inactivated influenza vaccine in adult hematopoietic stem cell transplantation patients A randomized trial of one versus two doses of influenza vaccine after allogeneic transplantation Recurrent deletions in the SARS-CoV-2 spike glycoprotein drive antibody escape Preventing measles in immunosuppressed cancer and hematopoietic cell transplantation patients: a position statement by the American Society for Transplantation and Cellular Therapy Factors associated with measles resurgence in the United States in the post-elimination era Effectiveness of parental cocooning as a vaccination strategy to prevent pertussis infection in infants: a case-control study Cocoon vaccination for influenza in patients with a solid tumor: a retrospective study. Support Care Cancer Vaccine-preventable infection morbidity of patients with chronic kidney disease and cocoon vaccination strategies Household transmission of SARS-CoV-2: a systematic review and meta-analysis General best practice guidelines for immunization: best practices guidance of the Advisory Committee on Immunization Practices (ACIP) IDSA clinical practice guideline for vaccination of the immunocompromised host The Advisory Committee on Immunization Practices' updated interim recommendation for allocation of COVID-19 vaccine-United States Understanding influenza vaccination rates and reasons for refusal in caregivers and household contacts of cancer patients COVID-19 Vaccination intent, perceptions, and reasons for not vaccinating among groups prioritized for early vaccination-United States Presentation of caregiverspecific vaccine-related information on National Cancer Institute designated cancer center websites Will SARS-CoV-2 become endemic?